# A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine

## TL;DR

This paper reviews how childhood ALL treatment has evolved from traditional chemotherapy to precision medicine over the past decade.

## Contribution

The paper highlights the shift to precision medicine and its impact on ALL treatment strategies and outcomes.

## Key findings

- Improved diagnostic techniques like minimal residual disease detection have enhanced treatment monitoring.
- Immunotherapies and targeted therapies are now integral to front-line ALL treatment protocols.
- Artificial intelligence is being integrated to further personalize and optimize treatment approaches.

## Abstract

Over the past decade, the management of childhood acute lymphoblastic leukemia (ALL) has undergone remarkable advancements. This review explores the transition from conventional chemotherapy protocols to precision medicine approaches, highlighting improvements in diagnostic techniques, therapeutic strategies, and personalized treatments within front-line protocols. Key developments include enhanced minimal residual disease detection, the advent of immunotherapies, targeted therapies, and the integration of artificial intelligence. Despite these advancements, challenges remain in ensuring global access and equity. This article discusses the current state of ALL treatment and anticipates future directions in the field.